

Cipla barred from selling Onbrez generic

BS REPORTER

New Delhi, 12 January

The high court had issued an injunction order in favour of global drug-giant Novartis, asking Cipla to stop selling the cheaper version of respiratory drug Onbrez. However, Cipla can sell the remaining stock, the court has ruled. Cipla, in its defence, had said there was not sufficient amount of the drug available in the market. A Cipla spokesperson said, "We are disappointed with the order. However, we fully comply with it. We will decide on the next course of action once we read the judgement."

The court has told Cipla to apply for a compulsory licence on the drug if the company feels the market does not have adequate supply.

After the launch of generic medicine, Cipla was selling it at ₹130 for every 10 pills, while the same is being sold at ₹677 every 10 pills by Novartis.

Novartis moved the high court in December last year, seeking to restrain Cipla from selling the generic version of Onbrez.

Patent